324 related articles for article (PubMed ID: 22457597)
1. Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.
Alameh M; Dejesus D; Jean M; Darras V; Thibault M; Lavertu M; Buschmann MD; Merzouki A
Int J Nanomedicine; 2012; 7():1399-414. PubMed ID: 22457597
[TBL] [Abstract][Full Text] [Related]
2. siRNA Delivery with Chitosan: Influence of Chitosan Molecular Weight, Degree of Deacetylation, and Amine to Phosphate Ratio on in Vitro Silencing Efficiency, Hemocompatibility, Biodistribution, and in Vivo Efficacy.
Alameh M; Lavertu M; Tran-Khanh N; Chang CY; Lesage F; Bail M; Darras V; Chevrier A; Buschmann MD
Biomacromolecules; 2018 Jan; 19(1):112-131. PubMed ID: 29211954
[TBL] [Abstract][Full Text] [Related]
3. Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis.
Lu HD; Zhao HQ; Wang K; Lv LL
Int J Pharm; 2011 Nov; 420(2):358-65. PubMed ID: 21911044
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA.
Malhotra M; Tomaro-Duchesneau C; Saha S; Kahouli I; Prakash S
Int J Nanomedicine; 2013; 8():2041-52. PubMed ID: 23723699
[TBL] [Abstract][Full Text] [Related]
5. Lipoplexes versus nanoparticles: pDNA/siRNA delivery.
Khurana B; Goyal AK; Budhiraja A; Aora D; Vyas SP
Drug Deliv; 2013 Feb; 20(2):57-64. PubMed ID: 23537464
[TBL] [Abstract][Full Text] [Related]
6. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
7. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
9. Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity.
Holzerny P; Ajdini B; Heusermann W; Bruno K; Schuleit M; Meinel L; Keller M
J Control Release; 2012 Jan; 157(2):297-304. PubMed ID: 21884740
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.
Jean M; Alameh M; De Jesus D; Thibault M; Lavertu M; Darras V; Nelea M; Buschmann MD; Merzouki A
Eur J Pharm Sci; 2012 Jan; 45(1-2):138-49. PubMed ID: 22085632
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies.
Fernandes JC; Qiu X; Winnik FM; Benderdour M; Zhang X; Dai K; Shi Q
Int J Nanomedicine; 2012; 7():5833-45. PubMed ID: 23209368
[TBL] [Abstract][Full Text] [Related]
12. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
13. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
[TBL] [Abstract][Full Text] [Related]
14. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing.
Malmo J; Sørgård H; Vårum KM; Strand SP
J Control Release; 2012 Mar; 158(2):261-8. PubMed ID: 22119955
[TBL] [Abstract][Full Text] [Related]
15. Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery.
Csaba N; Köping-Höggård M; Alonso MJ
Int J Pharm; 2009 Dec; 382(1-2):205-14. PubMed ID: 19660537
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles.
Cadete A; Figueiredo L; Lopes R; Calado CC; Almeida AJ; Gonçalves LM
Eur J Pharm Sci; 2012 Mar; 45(4):451-8. PubMed ID: 21986445
[TBL] [Abstract][Full Text] [Related]
17. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems.
Chen J; Tian B; Yin X; Zhang Y; Hu D; Hu Z; Liu M; Pan Y; Zhao J; Li H; Hou C; Wang J; Zhang Y
J Biotechnol; 2007 Jun; 130(2):107-13. PubMed ID: 17467097
[TBL] [Abstract][Full Text] [Related]
19. Layer by Layer Assembled Chitosan-Coated Gold Nanoparticles for Enhanced siRNA Delivery and Silencing.
Shaabani E; Sharifiaghdam M; De Keersmaecker H; De Rycke R; De Smedt S; Faridi-Majidi R; Braeckmans K; Fraire JC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467656
[TBL] [Abstract][Full Text] [Related]
20. Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery.
Ping Y; Liu C; Zhang Z; Liu KL; Chen J; Li J
Biomaterials; 2011 Nov; 32(32):8328-41. PubMed ID: 21840593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
